Sonnet BioTherapeutics Announces Generation And In Vitro Characterization Of Novel Drug Candidates SON-1411 And SON-1400
$SONN
Biotechnology: Pharmaceutical Preparations
Health Care
- Sonnet discovered and characterized a modified version of Interleukin-18 (IL-18Binding Protein Resistant or IL-18BPR) that exhibits wild-type binding to the IL-18 receptor (IL-18Rc), coupled with undetectable binding to the inhibitory IL-18 Binding Protein (IL-18BP)
- IL-18BPR was linked to Sonnet's proprietary tumor targeting FHAB platform, with or without single-chain wild-type IL-12
- The bifunctional SON-1411 molecule is manufactured in Chinese Hamster Ovary (CHO) cells, while the monofunctional SON-1400 molecule is made in E. coli; both have been highly purified and were bioactive in the receptor binding assays
- IL-18BPR and IL-12 could be combined for broad applications in oncology and cell-based therapies